Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
10.3969/j.issn.1672-7347.2013.06.002
- Author:
Xiangling TANG
1
;
Mengying CHEN
;
Weiru ZHANG
Author Information
1. Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
C-Reactive Protein;
metabolism;
Carotid Artery Diseases;
blood;
complications;
Case-Control Studies;
Female;
Humans;
Interleukin-6;
blood;
Male;
Middle Aged;
Nicotinamide Phosphoribosyltransferase;
blood;
Renal Insufficiency, Chronic;
blood;
complications;
Risk Factors
- From:
Journal of Central South University(Medical Sciences)
2013;38(6):553-559
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To determine the levels of visfatin in patients with chronic kidney disease (CKD) and to explore the relationship between visfatin levels and caroid atherosclerosis in CKD patients.
METHODS:A total of 180 CKD patients (102 non-dialyzed patients and 78 dialysis patients) and 42 healthy subjects enrolled in this study. The serum levels of visfatin, IL-6, and high sensitive C-reactive protein (hsCRP) were measured by ELISA. Common carotid arteries intima-media thickness (CCA-IMT), cross-sectional calculated intima-media thickness (c IMT) area and atherosclerotic plaque were detected by non-invasive high-resolution B-mode ultrasonography.
RESULTS:The serum levels of visfatin, IL-6 and hsCRP were significantly increased in CKD patients compared with age matched healthy subjects (P<0.01). The serum levels of visfatin, IL-6 and hsCRP in the dialyzed patients were significantly higher than those in non-dialyzed patients (P<0.05). Visfatin levels increased with the progression of renal dysfunction and inversely related to creatinine clearance (Ccr) in non-dialyzed patients (r=-0.415, P<0.05). Patients with carotid artery plaques showed significantly higher levels of visfatin[(34.22±7.96) ng/mL)] compared with those without plaques [(28.24±6.18) ng/mL, P<0.05]. The serum levels of visfatin were closely correlated with IL-6 (r=0.548, P<0.001), hsCRP (r=0.430, P<0.001), CCA-IMT (r=0.462, P<0.05), and c IMT area (r=0.411, P<0.05). After adjusting for GFR, age, gender, and other risk factors associated with atherosclerosis, multiple stepwise regression analysis showed that serum visfatin is a independent risk factor for CCA-IMT (β=0.433, P<0.01) and c IMT area (β=0.412, P<0.01).
CONCLUSION:The serum level of visfatin increase with the progression of CKD and should be considered to be a new risk factor for atherosclerosis in CKD.
